Replies to post #173559 on Biotech Values

[marthambles]

Deutsch Bank attempts to throw some cold water:

Deutsche Bank reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD) with a price target of $132.00. Comments follow new data from AbbVie (NYSE: ABBV).

Analyst Robyn Karnauskas said, "Gilead & Abbvie data with Riba looks relatively similar. However, Gilead's data without Riba is the likely key advantage & also no breakthroughs on Sovaldi. We also note Gilead's duration for naïve patients is lower at 8 wks ex Riba."

"We think Gilead’s IFN-free regimen (QD, one pill) is more convenient since it excludes Riba & does not have to be dosed twice a day," added the analyst. "Ultimately, we think payers and doctors will choose a regimen most likely to cure all patients with a single pill. We also think payers will be worried about relapse & expenses associated with them."

[biotech_researcher]

Very much agree.. I slowly, very slowly, accumulated a rather large position in the 18's, so I'm holding here.

[DewDiligence]

The risk in ENTA has been greatly reduced after today's data imo.

At a minimum, the $195M of regulatory milestones from ABBV for merely getting the 3-DAA regimen approved would now seem to be a fait accompli.